Monopar Therapeutics (MNPR) stock
MNPR's Quality Score rose 2 points on Tue, Oct 6, to -1. Traded heavy volume (2 chart checks started).
Follow MNPR's trial news. Pro members can get an alert when Monopar Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Holding it back
An $18M loss.
4 more reasons behind MNPR's -1, for Pro members
What's next for MNPR, and how long its cash lasts
From Monopar Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Its trials
Cash runway
Over 5 years
Dilution on the horizon
- Shelf registration (S-3, filed Aug 29, 2025)
Insiders
Director Christopher M Starr sold 8,400 shares on Oct 1, under a planned sale. 3 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 24 daysINOInovio Pharmaceuticals
INOINO-3107
- In 35 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 47 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why MNPR scores -1
PoorTrending up, 2 of 14 checks firingWhat the Quality Score means
Well below its own recent run. MNPR scores -1 today, against a median of 5.5 over its last 20 recorded sessions.
- +2Chart checks 2 of 14 firing right now, one point each
- −1Profit Lost $18M over the last four quarters, more than the $17M lost a year earlier, from the SEC filings
- Run-up adds
- Dilution subtracts
- Volatility subtracts
- Cash flow subtracts
What's next
Thu Nov 5: American Association for the Study…Industry event · date confirmed.
Expected to report Thu Nov 12
After its last 4 reports it closed -0.7% on average, higher 1 of 4 times.
What would turn MNPR's score around: 8 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
MNPR has 2 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1424.4
- MACD (12, 26, 9)Below signal
- 50-day average$105.85
- 200-day average$76.56
- ADX 1441.6
- Support$77.00
- Resistance$89.70
- Bollinger Bands (20, 2)Inside
- Volume2.0x
How MNPR ranks in Biotech
MNPR is #148 of 300 by Quality Score. The top three are shown with their scores, and more by name.
KNSA6/1419
ONC6/1418
EXEL6/1416
MLYSOpen for its score
MNOVOpen for its score
MPLTOpen for its score
MRNAOpen for its score
MNPR2/14-1
When does MNPR report earnings, and what happens after?
Expected to report Thu Nov 12 (in 37 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 12, 2026No time given | No time given | -4.1% | -3.9% | +7.8% |
| May 14, 2026No time given | No time given | -2.2% | -2.8% | +2.8% |
| Mar 27, 2026No time given | No time given | +0.1% | -1.5% | -0.8% |
| Nov 13, 2025Before open | Before open | -0.8% | +5.4% | +0.5% |
MNPR's officers and directors
Officers and directors with a Form 4 here in the last 3 months. Open one for their trades at every company.
About Monopar Therapeutics
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of MNPR's score, with the points and the reason
- All 14 checks on MNPR and on all 3,244 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on MNPR
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.